CDSCO Panel Approves J&J's Protocol Amendment Proposal For Amivantamab, Lazertinib combination
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major Johnson & Johnson's proposal for the protocol amendment of the fixed-dose combination ( FDC) anti-cancer drug Amivantamab Plus Lazertinib.
This came after the firm presented protocol amendment 4 dated 14 November 2023 protocol No.73841937NSC3003. The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions [Exon 19del] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).
Amivantamab is used alone or with other drugs to treat adults with non-small cell lung cancer that has spread and has an abnormal EGFR gene. It is used in patients whose cancer has not been treated with other anticancer therapy or has gotten worse during or after platinum chemotherapy.
The synergistic mechanisms of action of amivantamab, which targets the extracellular ligand binding domain, combined with lazertinib, which targets the intracellular active site, have the potential to more potently inhibit the EGFR pathway than either agent alone.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.